stockrow
Friday 6 November 2026
Export IRIX’s income statement to Excel — free account
IRIDEX Corporation
IRIX Healthcare Medical Devices
IRIDEX Corporation’s revenue for fiscal 2025 (year ended December 2025) was $52.7 million, up 8.23% from fiscal 2024.
- Revenue
- −7.41%
- EPS
- −16.7%
- Free cash flow
- +130.2%
- Total debt
- +3.27%
Quarter to June 2026, against a year earlier
0.68
0.00
0.00%
Follow IRIX
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.39 | 0.33 | 0.37 | 0.38 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
115.12 | (13.10) | 32.78 | (16.74) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.40 | 0.35 | 0.36 | 0.38 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(12.07) | (7.99) | (8.86) | (4.88) | |
EV/FCF |
(10.44) | (7.26) | (8.30) | (4.83) | |
Quick Ratio |
0.89 | 1.01 | 1.18 | 1.22 | |
Current Ratio |
1.82 | 1.92 | 1.91 | 1.94 | |
Net Debt/EBITDA |
1.39 | (10.64) | (5.25) | 1.84 | |
Debt/Assets |
13.92% | 13.32% | 12.81% | 13.07% | |
Debt/Equity |
1.04 | 0.80 | 0.76 | 0.79 | |
Asset Turnover |
1.75 | 1.68 | 1.81 | 1.73 | |
Operating CF/Net income |
(0.14) | 2.55 | (3.20) | 0.74 | |
Capex/Depreciation |
(0.13) | (0.25) | (0.23) | (0.03) | |
Research and Development Expense of Revenue |
7.45% | 7.67% | 6.45% | 7.79% | |
Selling, General and Administrative Expense of Revenue |
34.93% | 35.26% | 30.85% | 35.66% | |
Intangible Assets out of Total Assets |
0.07 | 0.07 | 0.07 | 0.07 | |
Share Based Compensation of Revenue |
1.69% | 1.79% | 1.45% | 0.74% | |
Graham Net Nets |
0.02 | 0.06 | 0.05 | 0.02 | |
Graham Number |
0.78 | 0.56 | 0.61 | 0.72 | |
Earnings Yield |
(17.39%) | (18.81%) | (22.81%) | (26.32%) | |
Free Cash Flow Yield |
(9.98%) | (14.49%) | (11.70%) | (20.57%) | |
Revenue per Share |
0.72 | 0.68 | 0.87 | 0.73 | |
Operating CF per Share |
0.01 | (0.08) | 0.03 | (0.07) | |
Capex per Share |
0.00 | (0.01) | (0.01) | 0.00 | |
Free Cash Flow per Share |
0.01 | (0.08) | 0.03 | (0.07) | |
Cash per Share |
0.27 | 0.27 | 0.36 | 0.33 | |
Shareholders Equity per Share |
0.21 | 0.27 | 0.29 | 0.28 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.21 | 0.27 | 0.29 | 0.28 | |
Free Cash Flow |
0.12 | (1.44) | 0.48 | (1.17) | |
Working Capital |
10.79 | 11.76 | 12.04 | 11.67 | |
Capital Expenditures |
(0.05) | (0.10) | (0.11) | (0.01) | |
Net Current Asset Value |
0.34 | 1.04 | 1.02 | 0.39 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.01 | 0.01 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
8.56 | 8.90 | 8.97 | 8.66 | |
Average Payables |
5.98 | 5.90 | 6.19 | 5.31 | |
Average Inventory |
9.09 | 9.73 | 9.35 | 9.12 | |
Average Assets |
29.42 | 31.26 | 29.14 | 29.25 | |
Average Common Equity |
(1.15) | (0.21) | 0.51 | 0.65 |
Columns are period end dates